Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives $12.23 Consensus Price Target from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX) has earned a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $12.2308.

Several equities analysts have commented on CMPX shares. Cantor Fitzgerald initiated coverage on shares of Compass Therapeutics in a report on Wednesday, December 3rd. They issued an “overweight” rating on the stock. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research note on Wednesday, November 5th. Compass Point set a $10.00 price target on shares of Compass Therapeutics in a report on Monday, October 6th. Citizens Jmp assumed coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They set a “market outperform” rating and a $10.00 price objective for the company. Finally, Lifesci Capital started coverage on Compass Therapeutics in a research report on Monday, October 6th. They issued an “outperform” rating and a $10.00 target price on the stock.

Institutional Trading of Compass Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. CIBC Bancorp USA Inc. bought a new stake in Compass Therapeutics in the 3rd quarter valued at about $37,000. Vivo Capital LLC raised its position in shares of Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Compass Therapeutics by 280.4% in the third quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock valued at $11,332,000 after buying an additional 2,386,367 shares during the period. Focus Partners Wealth boosted its stake in shares of Compass Therapeutics by 16.2% in the third quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock valued at $56,000 after buying an additional 2,206 shares during the period. Finally, Citadel Advisors LLC grew its position in Compass Therapeutics by 1,981.2% during the third quarter. Citadel Advisors LLC now owns 233,271 shares of the company’s stock worth $816,000 after buying an additional 245,671 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Stock Down 4.3%

NASDAQ CMPX opened at $5.16 on Monday. The firm’s 50 day moving average is $4.57 and its 200-day moving average is $3.52. The company has a market capitalization of $917.76 million, a PE ratio of -11.47 and a beta of 1.44. Compass Therapeutics has a 12-month low of $1.33 and a 12-month high of $5.86.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. As a group, sell-side analysts expect that Compass Therapeutics will post -0.36 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.